Previous Article | Next Article 
Journal of Clinical Microbiology, April 2000, p. 1444-1448, Vol. 38, No. 4
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Antipneumococcal Activity of Telithromycin by Agar
Dilution, Microdilution, E Test, and Disk Diffusion
Methodologies
Todd A.
Davies,1
Linda M.
Kelly,1
Michael R.
Jacobs,2 and
Peter C.
Appelbaum1,*
Department of Pathology, Hershey Medical
Center, Hershey, Pennsylvania 17033,1 and
Department of Pathology, Case Western Reserve
University, Cleveland, Ohio 441062
Received 13 October 1999/Returned for modification 26 November
1999/Accepted 3 January 2000
 |
ABSTRACT |
Agar dilution and microdilution (both in air) and E test and disk
diffusion (both in air and CO2) were used to test the
activity of telithromycin against 110 erythromycin-susceptible and 106 erythromycin-resistant pneumococci. The MICs at which 50 and 90% of
strains are inhibited (MIC50s and MIC90s,
respectively) for erythromycin-susceptible strains varied between 0.008 and 0.016 µg/ml and 0.016 and 0.03 µg/ml when the samples were
incubated in air. By comparison, telithromycin MIC50s and
MIC90s for erythromycin-resistant strains were in air 0.03 to 0.125 and 0.125 to 0.5 µg/ml, respectively. When agar dilution was
used as the reference method, essential agreement was found for 112 of
216 strains (51.9%) for microdilution, 168 of 216 (77.8%) for E test
in air, and 132 of 216 (61.1%) for E test in CO2. With the
exception of four strains tested by E test in CO2, all
organisms were susceptible to a proposed telithromycin susceptibility
breakpoint of
1 µg/ml. By disk diffusion with 15-µg telithromycin
disks, all strains but one had zones of inhibition
19 mm in diameter
when incubated in CO2, while all strains had zone diameters
of
22 mm when incubated in air. Zone diameters in air were generally
4 to 5 mm larger than in CO2. By all methods, MICs and
zones of all erythromycin-resistant strains occurred in clusters
separated from those seen with erythromycin-susceptible strains. The
results for macrolide-resistant strains with erm and
mef resistance determinants were similar. The results show that (i) telithromycin is very active against erythromycin-susceptible and -resistant strains irrespective of macrolide resistance mechanism; (ii) susceptibility to telithromycin can be reliably tested by the
agar, microdilution, E test, and disk diffusion methods; and (iii)
incubation in CO2 led to smaller zones by disk diffusion and higher MICs by E test, but at a susceptible MIC breakpoint of
1
µg/ml and a susceptible zone diameter cutoff of
19 mm in CO2, 215 of 216 strains were found to be susceptible to telithromycin.
 |
INTRODUCTION |
Streptococcus pneumoniae
continues to be a significant cause of morbidity and mortality in
humans and is the leading cause of bacterial pneumonia, sinusitis, and
otitis media and an important cause of meningitis (2, 4,
10-12). The past 5 years have witnessed a dramatic worldwide
increase in the incidence of pneumococcal strains which are resistant
to penicillin G and other
-lactam and non-
-lactam antimicrobials,
such as macrolides, clindamycin, tetracycline, chloramphenicol, and
trimethoprim-sulfamethoxazole (5, 8, 13). The problem has
been exacerbated by the tendency of these strains to spread from
country to country and from continent to continent (16, 17).
In the United States, a recent study has shown that for 23.6% of 1,527 clinically significant pneumococci from 30 U.S. centers, penicillin
MICs were
0.125 µg/ml, with 14.1% being intermediate and 9.5%
being resistant (8). Penicillin-resistant pneumococci were
more likely to be resistant to macrolides and other unrelated agents,
such as chloramphenicol, tetracycline, and
trimethoprim-sulfamethoxazole. Erythromycin resistance among
pneumococci has increased in the United States from approximately 0.2%
in the late 1980s to 5 and 15% in some areas of the country (5,
8, 22). In the survey described above (8), 20% of
penicillin-intermediate pneumococcal strains and 49% of
penicillin-resistant strains were erythromycin resistant. In a recently
published study from our laboratory performed in 1997 (13),
49.6% of 1,476 pneumococcal strains obtained from outpatients in six
geographic regions of the United States were penicillin susceptible,
17.9% were intermediate, and 32.5% were penicillin resistant. In the
latter survey, 95% of penicillin-susceptible, 65% of intermediate,
and 33% of penicillin-resistant strains were macrolide susceptible.
Strains for which penicillin MICs were increased were also more likely
to be multiresistant (13).
Pneumococcal strains that are resistant to erythromycin exhibit
cross-resistance to other macrolides and azalides such as azithromycin,
clarithromycin, and roxithromycin (7, 9, 24). Telithromycin
(HMR 3647), a new ketolide (1), has been shown to have low
MICs for both macrolide-susceptible and macrolide-resistant pneumococcal strains (6, 14, 21; D. Felmingham,
M. J. Robbins, A. Leakey, R. Cooke, C. Dencer, H. Solman, G. L. Ridgway, R. N. Grüneberg, and A. Bryskier, Abstr. 37th
Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-116, 1997).
Although MICs are slightly higher for macrolide-resistant strains, all
strains are susceptible at
2.0 µg/ml, irrespective of the macrolide
resistance mechanism (21).
Currently, the National Committee for Clinical Laboratory Standards
(NCCLS) recommends incubation in air for microdilution testing and in
CO2 for disk diffusion (18, 19). The
manufacturer of the E test (AB Biodisk, Solna, Sweden) also recommends
incubation in CO2 for testing of S. pneumoniae
because 5 to 10% of strains do not grow without CO2 on
primary isolation (7, 15). Because incubation in
CO2 has previously been shown to affect macrolide MICs for
S. pneumoniae (7, 9, 24), we tested activity by
agar dilution and microdilution in air and disk diffusion and E test in
air as well as CO2 atmospheres. We are aware of no previous published data on incubation in air compared with CO2 for ketolides.
 |
MATERIALS AND METHODS |
Bacteria and antibiotics.
A total of 216 isolates of
S. pneumoniae (collected between 1995 and 1997 from various
laboratories in the United States) were selected from our culture
collection for testing. All strains had been subcultured several times
prior to use and all grew well in air. Cultures were stored at
70°C
in double-strength skim milk (Difco Laboratories, Detroit, Mich.).
Telithromycin and erythromycin were obtained from Hoechst Marion
Roussel Anti-infectives, Romainville, France. Powders were stored at
4°C.
Macrolide resistance mechanism determination.
All strains
were screened for macrolide susceptibility by the double disk method
with erythromycin and clindamycin disks (18). Strains with
erythromycin zone diameters of
20 mm were tested for the presence of
the ermB and mefE genes as follows. DNA was extracted from isolated strains derived from single colonies with the
Prep-A-Gene kit (Bio-Rad, Hercules, Calif.) as recommended by the
manufacturer. Previously described primer sets for amplification of the
ermB and mefE genes were used (20,
23). An initial denaturing step at 96°C for 3 min and a final
elongation step at 72°C for 5 min were performed for each PCR run.
The ermB and mefE genes were amplified by 30 cycles of three steps: 96°C for 60 s, 52°C for 60 s, and
72°C for 60 s. The PCR products for ermB genes were
640 bp, and those for mefE genes were 348 bp. Amplifications were carried out in a final volume of 50 µl in a GeneAmp PCR system 2400 (Perkin-Elmer, Foster City, Calif.). The final PCR mixture contained 10 mM Tris-HCl (pH 8.3); 50 mM KCl; 2.0 mM MgCl2;
200 µM concentrations of each of the deoxynucleotides dATP, dCTP, dGTP, and dTTP; 30 to 50 pmol of each primer set; 1 ng of template DNA;
and 2.5 U of Taq polymerase (Fisher BioTech). Samples of each PCR product were then electrophoresed on 2% agarose gels (Bio-Rad) and stained in ethidium bromide (0.5 µg/ml) in 0.5× Tris-borate-EDTA buffer. PCR products were visualized under UV illumination, and their sizes were estimated with PCR markers (Promega,
Madison, Wis.). Negative controls ruled out the possible influence of
amplicon modification.
Agar dilution MICs.
Agar dilution MICs were determined by
the methods used in our laboratory (7) on Mueller-Hinton
agar supplemented with 5% sheep blood, incorporating telithromycin and
erythromycin at concentrations of 0.002 to 64 µg/ml in doubling
dilutions. Inocula were prepared by suspending growth from overnight
cultures in sterile saline to a turbidity of a 0.5 McFarland standard.
Final inocula contained 104 CFU/spot. Plates were
inoculated with a Steers replicator with 3-mm inoculating pins and
incubated overnight at 35°C in air. The lowest concentration of
antibiotic resulting in no growth was read as the MIC. The quality
control strains Staphylococcus aureus ATCC 29213 and
S. pneumoniae ATCC 49619 were included in each run. Inoculum
checks were performed for each strain.
Microdilution MICs.
Telithromycin MICs were determined by
the method recommended by the NCCLS (19), using
cation-adjusted Mueller-Hinton broth (Difco Laboratories) supplemented
with 5% lysed defibrinated horse blood. Suspensions with a turbidity
equivalent to that of a 0.5 McFarland standard were prepared by
suspending growth from blood agar plates in 2 ml of sterile saline.
Suspensions were further diluted 1:10 to obtain a final inoculum of
5 × 105 CFU/ml. Trays were incubated overnight in
ambient air at 35°C. Standard quality control strains and inoculum
checks (as above) were included.
E test MICs.
Mueller-Hinton plates supplemented with 5%
sheep blood (BBL Microbiology Systems, Cockeysville, Md.) were
inoculated with a 0.5 McFarland suspension harvested from overnight
growth on plates, and telithromycin E test strips (AB Biodisk) were
placed on each plate (7, 15). After overnight incubation at
35°C, the MIC was read where the ellipse of growth inhibition
intersected the strip. E test MICs were determined both in air and in
CO2. Standard quality control strains (see above) were used
with each run.
Disk diffusion.
Disk diffusion was performed by standard
NCCLS methodology (19) using Mueller-Hinton plates
supplemented with 5% sheep blood (source as above), inoculated with a
0.5 McFarland suspension; 15-µg telithromycin disks (BBL Microbiology
Systems) were placed on the plates. After overnight incubation in both
air and 5% CO2 at 35°C, the diameters of zones of
inhibition were measured with calipers. Standard quality control
strains (see above) were used with each run.
Interpretation of results.
For telithromycin, provisional
breakpoints of
1.0 µg/ml for susceptible, 2.0 µg/ml for
intermediate, and
4.0 µg/ml for resistant results were used.
Essential agreement was defined as the MIC by one method being within 1 log2 dilution of the MIC by agar dilution (taken as the
reference method). Interpretative category discrepancies were defined
as very major discrepancies when the reference method showed resistance
and the comparative method showed susceptibility; major discrepancies
occurred when the reference method showed susceptibility and the
comparative method showed resistance; and minor discrepancies occurred
when an intermediate result was obtained with one method and a
resistant or susceptible result was obtained with the other
(7).
 |
RESULTS |
Of the 216 isolates included in this study, 110 were erythromycin
and clindamycin susceptible by disk diffusion testing, with erythromycin MICs being
0.12 µg/ml by agar and microdilution. The
remaining 106 isolates were erythromycin resistant (erythromycin MICs,
0.5 µg/ml), with 32 being clindamycin susceptible and positive for
mefE gene products. All remaining 74 macrolide-resistant
strains were positive for erm gene products.
The telithromycin MIC results for the four susceptibility testing
methods are presented in Table 1 and Fig.
1. The MICs at which 50% and 90% of the
strains are inhibited (MIC50s and MIC90s, respectively) for the erythromycin-susceptible strains varied between
0.008 and 0.016 µg/ml and 0.016 and 0.03 µg/ml, respectively, for
methods using incubation in air. By comparison, the telithromycin MIC50s and MIC90s in air of
erythromycin-resistant strains were 0.03 to 0.125 and 0.125 to 0.5 µg/ml, respectively. By the E test method with incubation in
CO2, telithromycin MIC50s and
MIC90s were 0.03 and 0.06 and for erythromycin-susceptible
strains, respectively, and 0.25 and 0.5 µg/ml for
erythromycin-resistant strains, respectively. Table
2 presents agar dilution results for
erythromycin-susceptible and -resistant strains. As can be seen,
telithromycin MIC50s and MIC90s rose from 0.016 and 0.016 µg/ml for the erythromycin-susceptible group to 0.06 and
0.5 µg/ml for the erythromycin-resistant group, compared to
erythromycin MICs of 0.03 and 0.06 µg/ml and >64 and >64 µg/ml
for the erythromycin-susceptible and -resistant groups, respectively.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
Histograms of telithromycin MICs for
erythromycin-susceptible (solid bars) and -resistant (open bars)
strains.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Comparison of agar dilution MIC results for
erythromycin-susceptible (n = 110) and
erythromycin-resistant (n = 106) strains
|
|
The disk diffusion results are shown in Fig.
2. Mean telithromycin disk diffusion zone
diameters were 26.7 mm in CO2, compared with 32.9 mm in
air. For erythromycin-susceptible and -resistant groups, mean zone
diameters were 28.5 and 24.9 mm, respectively, in CO2,
compared to 34.9 and 30.0 mm, respectively, in air. For incubation in
CO2, 215 of 216 strains were susceptible at a zone diameter
breakpoint of
19 mm, while all strains were susceptible in air at a
zone diameter breakpoint of
22 mm. A scatter plot of telithromycin
disk diffusion zones in CO2 versus agar dilution MICs is
presented in Fig. 3.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 2.
Disk diffusion histograms with incubation in air (a) and
CO2 (b) for erythromycin-susceptible (solid bars) and
-resistant (open bars) strains.
|
|

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Scatter plot comparison of disk diffusion zone diameters
in CO2 with agar dilution MICs in air.
|
|
Categorical discrepancies with the four methods are presented in Table
3. The number of strains with essential
agreement varied between 47 (21.8%) and 168 (77.8%), depending upon
which methods were being compared and whether CO2 was used
as opposed to air. Minor discrepancies were obtained with the E test
incubated in CO2 for one strain, and major discrepancies
for three strains were obtained with the E test compared with agar and
microdilution.
The effect of incubation in CO2 on the susceptibility
results showed that incubation of E tests in CO2 resulted
in MICs approximately 1 dilution higher and zone diameters 4 to 5 mm
narrower than those obtained with incubation in air (Table 1; Fig. 1
and 2). Additionally, although all strains were susceptible to
telithromycin by agar dilution, microdilution, and E test incubated in
air, four strains gave telithromycin MICs between 2 and 8 µg/ml when
E tests were incubated in CO2, yielding one minor and three
major discrepancies with the breakpoints used, irrespective of which
susceptibility method was used as the reference. The MICs and zones for
erythromycin-resistant strains occurred in clusters different from
those seen with erythromycin-susceptible strains. The telithromycin
MICs for erythromycin-resistant strains were similar irrespective of
macrolide resistance mechanism.
 |
DISCUSSION |
The results of this study confirm the excellent antipneumococcal
activity of telithromycin irrespective of erythromycin susceptibility, as reported previously (1). Clustering of MICs depended on the erythromycin susceptibility of the strains (21). The
agar and microdilution methods, both with incubation in air, produced similar MIC values. When E tests were incubated in air, excellent correlation with the results of the agar and microdilution methods was
obtained. However, when E tests were incubated in CO2, MICs rose, generally by 1 dilution. With a preliminary susceptible breakpoint of
1.0 µg/ml, all strains were telithromycin susceptible by the three MIC methods in air; however, incubation of E tests in
CO2 resulted in four strains for which telithromycin MICs
were increased to between 2 and 4 µg/ml.
Disk diffusion tests showed that, with the exception of one strain,
zone diameters in CO2 of
19 mm corresponded to
telithromycin MICs of
1.0 µg/ml. In air, disk diffusion zone
diameters of
22 mm corresponded with telithromycin MICs of
1.0
µg/ml in all 216 strains tested. NCCLS recommends incubation of
S. pneumoniae in air for agar dilution and microdilution but
in CO2 for disk diffusion, as is also the recommendation of
the manufacturer of the E test. In previous studies, we have reported
results similar to this CO2 effect on telithromycin
susceptibilities with other macrolides (9, 24). Because of
the higher MICs observed with incubation in CO2, there is a
need to determine macrolide and ketolide MICs in air as well as in
increased CO2 (as used in the current study) to allow
reliable testing by the E test method in the clinical laboratory.
In summary, our results show that (i) telithromycin is active against
erythromycin-susceptible and -resistant strains irrespective of
macrolide resistance mechanism, although MICs for
erythromycin-resistant strains are higher; (ii) susceptibility to
telithromycin may be reliably tested by agar, microdilution, E test,
and disk diffusion; and (iii) disk diffusion tests gave narrower zones
and E tests gave higher MICs when plates were incubated in
CO2 than when incubated in air, but at a preliminary
breakpoint of
1 µg/ml and zone diameter of
19 mm
(CO2), all strains but one were telithromycin susceptible irrespective of incubation atmosphere or method. More information from
clinical or animal data is required before breakpoints can be firmly
established and recommended.
 |
ACKNOWLEDGMENT |
This study was supported by a grant from Hoechst Marion Roussel
Anti-infectives.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathology, Hershey Medical Center, 500 University Dr., Hershey, PA
17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail:
pappelbaum{at}psghs.edu.
 |
REFERENCES |
| 1.
|
Agouridas, C.,
A. Bonnefoy, and J. F. Chantot.
1997.
Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens.
Antimicrob. Agents Chemother.
41:2149-2158[Abstract].
|
| 2.
|
Appelbaum, P. C.
1992.
Antimicrobial resistance in Streptococcus pneumoniae an overview.
Clin. Infect. Dis.
15:77-83[Medline].
|
| 3.
|
Arthur, M.,
C. Molinas,
C. Mabilat, and P. Courvalin.
1990.
Detection of erythromycin resistance by the polymerase chain reaction in conserved regions of erm rRNA methylase genes.
Antimicrob. Agents Chemother.
34:2024-2026[Abstract/Free Full Text].
|
| 4.
|
Block, S.
1997.
Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media.
Pediatr. Infect. Dis. J.
16:449-456[CrossRef][Medline].
|
| 5.
|
Breiman, R. F.,
J. C. Butler,
F. C. Tenover,
J. A. Elliott, and R. R. Facklam.
1994.
Emergence of drug-resistant pneumococcal infections in the United States.
JAMA
271:1831-1835[Abstract].
|
| 6.
|
Bryskier, A.,
C. Agouridas, and J.-F. Chantot.
1996.
Ketolides: new semisynthetic 14-membered ring macrolides, p. 39-50.
In
S. H. Zinner, L. S. Young, J. F. Acar, and H. C. Neu (ed.), Expanding indications for the new macrolides, azalides and streptogramins. Marcel Dekker, New York, N.Y.
|
| 7.
|
Clark, C. L.,
M. R. Jacobs, and P. C. Appelbaum.
1998.
Antipneumococcal activities of levofloxacin and clarithromycin as determined by agar dilution, microdilution, E-test, and disk diffusion methodologies.
J. Clin. Microbiol.
36:3579-3584[Abstract/Free Full Text].
|
| 8.
|
Doern, G. V.,
A. Brueggemann,
H. P. Holley, and A. M. Rauch.
1996.
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.
Antimicrob. Agents Chemother.
40:1208-1213[Abstract].
|
| 9.
|
Fasola, E. L.,
S. Bajaksouzian,
P. C. Appelbaum, and M. R. Jacobs.
1997.
Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods.
Antimicrob. Agents Chemother.
41:129-134[Abstract].
|
| 10.
|
Friedland, I. R., and G. S. Istre.
1992.
Management of penicillin-resistant pneumococcal infections.
Pediatr. Infect. Dis. J.
11:433-435[Medline].
|
| 11.
|
Friedland, I. R., and G. H. McCracken, Jr.
1994.
Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.
N. Engl. J. Med.
331:377-382[Free Full Text].
|
| 12.
|
Jacobs, M. R.
1992.
Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.
Clin. Infect. Dis.
15:119-127[Medline].
|
| 13.
|
Jacobs, M. R.,
S. Bajaksouzian,
A. Zilles,
G. Lin,
G. A. Pankuch, and P. C. Appelbaum.
1999.
Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study.
Antimicrob. Agents Chemother.
43:1901-1908[Abstract/Free Full Text].
|
| 14.
|
Jones, R. N., and D. J. Biedenbach.
1997.
Antimicrobial activity of RU-66647, a new ketolide.
Diagn. Microbiol. Infect. Dis.
27:7-12[CrossRef][Medline].
|
| 15.
|
Jones, R. N.,
M. E. Erwin, and J. L. Croco.
1996.
Critical appraisal of E test for the detection of fluoroquinolone resistance.
J. Antimicrob. Chemother.
38:21-25[Abstract/Free Full Text].
|
| 16.
|
McDougal, L. K.,
R. Facklam,
M. Reeves,
S. Hunter,
J. M. Swenson,
B. C. Hill, and F. C. Tenover.
1992.
Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States.
Antimicrob. Agents Chemother.
36:2176-2184[Abstract/Free Full Text].
|
| 17.
|
Munoz, R.,
J. M. Musser,
M. Crain,
D. E. Briles,
A. Marton,
A. J. Parkinson,
U. Sorensen, and A. Tomasz.
1992.
Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis.
Clin. Infect. Dis.
15:112-118[Medline].
|
| 18.
|
National Committee for Clinical Laboratory Standards.
1997.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS publication no. M7-A4.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 19.
|
National Committee for Clinical Laboratory Standards.
1997.
Performance standards for antimicrobial disk susceptibility tests. NCCLS publication no. M2-A6.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 20.
|
Pankuch, G. A.,
S. A. Jueneman,
T. A. Davies,
M. R. Jacobs, and P. C. Appelbaum.
1998.
In vitro selection of resistance to four -lactams and azithromycin in Streptococcus pneumoniae.
Antimicrob. Agents Chemother.
42:2914-2918[Abstract/Free Full Text].
|
| 21.
|
Pankuch, G. A.,
M. A. Visalli,
M. R. Jacobs, and P. C. Appelbaum.
1998.
Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.
Antimicrob. Agents Chemother.
42:624-630[Abstract/Free Full Text].
|
| 22.
|
Spika, J. S.,
R. R. Facklam,
B. D. Plikaytis,
M. J. Oxtoby, and the Pneumococcal Surveillance Working Group.
1991.
Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987.
J. Infect. Dis.
163:1273-1278[Medline].
|
| 23.
|
Sutcliffe, J.,
T. Grebe,
A. Tait-Kamradt, and L. Wondrack.
1996.
Detection of erythromycin-resistant determinants by PCR.
Antimicrob. Agents Chemother.
40:2562-2566[Abstract].
|
| 24.
|
Visalli, M. A.,
M. R. Jacobs, and P. C. Appelbaum.
1997.
Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.
Antimicrob. Agents Chemother.
41:1867-1870[Abstract].
|
Journal of Clinical Microbiology, April 2000, p. 1444-1448, Vol. 38, No. 4
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Rantala, M., Haanpera-Heikkinen, M., Lindgren, M., Seppala, H., Huovinen, P., Jalava, J., the Finnish Study Group for Antimicrobial Resistan,
(2006). Streptococcus pneumoniae Isolates Resistant to Telithromycin.. Antimicrob. Agents Chemother.
50: 1855-1858
[Abstract]
[Full Text]
-
Samore, M. H., Lipsitch, M., Alder, S. C., Haddadin, B., Stoddard, G., Williamson, J., Sebastian, K., Carroll, K., Ergonul, O., Carmeli, Y., Sande, M. A.
(2006). Mechanisms by Which Antibiotics Promote Dissemination of Resistant Pneumococci in Human Populations. Am J Epidemiol
163: 160-170
[Abstract]
[Full Text]
-
Faccone, D., Andres, P., Galas, M., Tokumoto, M., Rosato, A., Corso, A.
(2005). Emergence of a Streptococcus pneumoniae Clinical Isolate Highly Resistant to Telithromycin and Fluoroquinolones. J. Clin. Microbiol.
43: 5800-5803
[Abstract]
[Full Text]
-
Rantala, M., Huikko, S., Huovinen, P., Jalava, J., the Finnish Study Group for Antimicrobial Resistan,
(2005). Prevalence and Molecular Genetics of Macrolide Resistance among Streptococcus pneumoniae Isolates Collected in Finland in 2002. Antimicrob. Agents Chemother.
49: 4180-4184
[Abstract]
[Full Text]
-
Tessier, P. R., Mattoes, H. M., Dandekar, P. K., Nightingale, C. H., Nicolau, D. P.
(2005). Pharmacodynamic Profile of Telithromycin against Macrolide- and Fluoroquinolone-Resistant Streptococcus pneumoniae in a Neutropenic Mouse Thigh Model. Antimicrob. Agents Chemother.
49: 188-194
[Abstract]
[Full Text]
-
Tellier, G., Niederman, M. S., Nusrat, R., Patel, M., Lavin, B.
(2004). Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother
54: 515-523
[Abstract]
[Full Text]
-
Farrell, D. J., Felmingham, D.
(2004). Activities of Telithromycin against 13,874 Streptococcus pneumoniae Isolates Collected between 1999 and 2003. Antimicrob. Agents Chemother.
48: 1882-1884
[Abstract]
[Full Text]
-
Jorgensen, J. H., Crawford, S. A., McElmeel, M. L., Whitney, C. G.
(2004). Activities of Cethromycin and Telithromycin against Recent North American Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother.
48: 605-607
[Abstract]
[Full Text]
-
Syrogiannopoulos, G. A., Grivea, I. N., Ednie, L. M., Bozdogan, B., Katopodis, G. D., Beratis, N. G., Davies, T. A., Appelbaum, P. C.
(2003). Antimicrobial Susceptibility and Macrolide Resistance Inducibility of Streptococcus pneumoniae Carrying erm(A), erm(B), or mef(A). Antimicrob. Agents Chemother.
47: 2699-2702
[Abstract]
[Full Text]
-
Kozlov, R. S., Bogdanovitch, T. M., Appelbaum, P. C., Ednie, L., Stratchounski, L. S., Jacobs, M. R., Bozdogan, B.
(2002). Antistreptococcal Activity of Telithromycin Compared with Seven Other Drugs in Relation to Macrolide Resistance Mechanisms in Russia. Antimicrob. Agents Chemother.
46: 2963-2968
[Abstract]
[Full Text]
-
Nagai, K., Appelbaum, P. C., Davies, T. A., Kelly, L. M., Hoellman, D. B., Andrasevic, A. T., Drukalska, L., Hryniewicz, W., Jacobs, M. R., Kolman, J., Miciuleviciene, J., Pana, M., Setchanova, L., Thege, M. K., Hupkova, H., Trupl, J., Urbaskova, P.
(2002). Susceptibilities to Telithromycin and Six Other Agents and Prevalence of Macrolide Resistance Due to L4 Ribosomal Protein Mutation among 992 Pneumococci from 10 Central and Eastern European Countries. Antimicrob. Agents Chemother.
46: 371-377
[Abstract]
[Full Text]
-
Nagai, K., Appelbaum, P. C., Davies, T. A., Kelly, L. M., Hoellman, D. B., Andrasevic, A. T., Drukalska, L., Hryniewicz, W., Jacobs, M. R., Kolman, J., Miciuleviciene, J., Pana, M., Setchanova, L., Thege, M. K., Hupkova, H., Trupl, J., Urbaskova, P.
(2002). Susceptibility to Telithromycin in 1,011 Streptococcus pyogenes Isolates from 10 Central and Eastern European Countries. Antimicrob. Agents Chemother.
46: 546-549
[Abstract]
[Full Text]
-
Nagai, K., Davies, T. A., Ednie, L. M., Bryskier, A., Palavecino, E., Jacobs, M. R., Appelbaum, P. C.
(2001). Activities of a New Fluoroketolide, HMR 3787, and Its (Des)-Fluor Derivative RU 64399 Compared to Those of Telithromycin, Erythromycin A, Azithromycin, Clarithromycin, and Clindamycin against Macrolide-Susceptible or -Resistant Streptococcus pneumoniae and S. pyogenes. Antimicrob. Agents Chemother.
45: 3242-3245
[Abstract]
[Full Text]